Clinical trials: Plasmodium Vivax Malaria
Malaria
Effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar
In Myanmar, community health workers, known as malaria volunteers, have played a key role in reducing the malaria burden in the malaria control phase, providing essential malaria services in rural areas where the coverage of…
- Trial name
- NCT04695886
- Testing
- Community-delivered Integrated Malaria Elimination (CIME) intervention model
- Volunteers
- 6,440 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria
Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults
Background: Malaria is a disease carried by mosquitoes in tropical countries around the world. It can cause symptoms like fever, body aches, and weakness.
- Trial name
- NCT05913973
- Testing
- Pvs230D1-EPA/Matrix-M
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vivax Malaria
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
For the treatment of P.vivax the standard treatment is chloroquine. There is a growing body of evidence suggesting that pregnant women may require different doses of drugs, including antimalarials due to the physiological changes…
- Trial name
- KCP (NCT01546961)
- Testing
- Chloroquine
- Where
- Thailand
- Volunteers
- 49 people
- Sponsor
- University of Oxford
Malaria
Malaria Active Epidemiology and Treatment Study
An observational cohort and malaria treatment study in Cambodia.
- Trial name
- NCT01280162
- Testing
- Dihydroartemisinin piperaquine
- Where
- Cambodia
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Vivax Malaria
Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
This research is intended to study the efficacy of chloroquine (CQ) and primaquine (PQ) for Plasmodium vivax (P.vivax) infection, and also to study the recurrence rate among patients with P.vivax malaria on standard doses of CQ…
- Trial name
- NCT01716260
- Testing
- Chloroquine, Primaquine
- Where
- Bhutan
- Volunteers
- 24 people
- Sponsor
- Menzies School of Health Research
Vivax Malaria
Methylene Blue Against Vivax Malaria in Ethiopia
Feasibility of methylene blue-based combination therapy in the radical treatment of adult patients with Plasmodium vivax malaria in Ethiopia: a randomised controlled pilot trial Study rationale: Elimination has become the goal of…
- Trial name
- BlueAL (NCT02696928)
- Testing
- Artemeter-Lumefantrine and MB (combination therapy), Artemeter-Lumefantrine (combination therapy), Artemeter-Lumefantrine and Primaquine (combination therapy)
- Sponsor
- Heidelberg University
Malaria, Vivax, Malaria, Falciparum
Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon
The purpose of this study is to determine the efficacy of pyrimethamine/sulfdoxine (Fansidar®) for the treatment of uncomplicated falciparum malaria in the Peruvian Amazon.
- Trial name
- NCT00951106
- Testing
- Pyrimethamine/sulfdoxine (Fansidar)
- Where
- Peru
- Sponsor
- Walter Reed Army Institute of Research (WRAIR)
Malaria, Vivax, G6PD Deficiency
Assessing a Risk Model for G6PD Deficiency
A clinical study designed to develop and inform an individual risk of hemolysis model based on individual red blood cell G6PD levels.
- Trial name
- NCT03337152
- Testing
- primaquine, chloroquine + primaquine
- Where
- Thailand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Vivax
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
This is a prospective, double-blind, double-dummy, multicenter, comparative study. A total of 300 subjects will be randomized to treatment on Day 1, of which a minimum of 50 female subjects must be enrolled that display moderate…
- Trial name
- NCT02216123
- Testing
- Tafenoquine, Chloroquine, Primaquine
- Where
- 10 sites in Brazil, Colombia and 4 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Malaria
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Background: Malaria is a disease caused by parasites transmitted to people by mosquitoes. Around the world, there were 241 million cases and 627,000 deaths from malaria in 2020.
- Trial name
- NCT06607003
- Testing
- P. vivax challenge agent derived from PvHMB-CCE001
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
The primary objective of this clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (180:60 mg) with that of standard chloroquine therapy in children and adults with acute…
- Trial name
- NCT04368910
- Testing
- Pyronaridine - artesunate, Chloroquine
- Where
- 2 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Medicines for Malaria Venture
Vivax Malaria
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
In Southeast Asia, Plasmodium vivax (Pv) infection reaches 50-80% and bears a greater burden of disease than Plasmodium falciparum (Pf).
- Trial name
- NCT01640574
- Testing
- Dihydroartemisinin-Piperaquine, Chloroquine
- Where
- Thailand
- Volunteers
- 680 people
- Sponsor
- University of Oxford
Advanced Ovarian Cancer
Plasmodium Immunotherapy for Advanced Ovarian Cancer
The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer.
- Trial name
- NCT05924776
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Malaria
Ethiopia Malaria Therapeutic Efficacy Study
In this stdy, patients aged above 6 months with symptomatic malaria presenting to health centers will be enrolled for treatment with artemether-lumefantrine for P.
- Trial name
- NCT01052584
- Testing
- Chloroquine- P. vivax, Artemether-Lumefantrine: P. vivax, Artemether-lumefantrine: P. falciparum
- Where
- 2 sites in Ethiopia
- Volunteers
- 354 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria
G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)
SB-252263 (Tafenoquine, TQ) is an 8-aminoquinoline (8-AQ) antimalarial drug being developed by GlaxoSmithKline (GSK), the U.S. Army Medical Research and Materiel Command (USAMRMC) and Medicines for Malaria Venture (MMV).
- Trial name
- NCT01205178
- Testing
- Chloroquine, Primaquine, Tafenoquine
- Where
- 2 sites in Thailand
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum, Malaria, Vivax
A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.
The primary aim of the comparative trial is to assess the relative safety and efficacy of two artemisinin containing regimens: amodiaquine plus artesunate (AAQ) and artekin both administered once daily for 3 days.
- Trial name
- NCT00157885
- Testing
- Amodiaquine plus artesunate; Artekin
- Where
- Indonesia
- Volunteers
- 400 people
- Sponsor
- Menzies School of Health Research
Malaria, Vivax Malaria
Eight Week Primaquine Regimen for the Treatment of Vivax Malaria
Plasmodium vivax represents a major health problem throughout the tropics. Outside Africa it accounts for over 50% of cases, affecting an estimated 70-80 million people per year.
- Trial name
- NCT00158587
- Testing
- primaquine
- Volunteers
- 150 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum, Plasmodium Vivax Malaria
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
This study, conducted at Johns Hopkins University Center for Immunization Research in Washington DC, will test the safety and immune response of healthy volunteers to two experimental malaria vaccines.
- Trial name
- NCT00295581
- Testing
- PpPfs25/ISA51 & ScPvs25/ISA51
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day
- Trial name
- NCT01524341
- Testing
- KAE609
- Where
- 3 sites in Thailand
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Vivax
Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria
The purpose of this study was to determine whether the proposed first line treatment for falciparum malaria in this region (sulfadoxine-pyrimethamine + artesunate) would be no worse a treatment for vivax malaria that the standard…
- Trial name
- NCT00486694
- Testing
- Sulfadoxine-pyrimethamine + artesunate, Chloroquine
- Volunteers
- 190 people
- Sponsor
- London School of Hygiene and Tropical Medicine